Rockwell Medical (NASDAQ:RMTI) is a specialty pharmaceutical company focused on therapies for chronic kidney disease and related disorders. The company’s primary product, Triferic™ (ferric pyrophosphate citrate), is designed to maintain iron balance in hemodialysis patients by replacing iron losses directly through the dialysis process. In addition, Rockwell Medical markets Calcitriol Injection, an active form of vitamin D indicated for patients with chronic renal failure. These products target key supportive care needs in the nephrology market.
Founded in 1992 and headquartered in Wixom, Michigan, Rockwell Medical has built its business through research, development and strategic licensing partnerships. The company obtained FDA approval for Triferic in 2015 and subsequently secured reimbursement coverage with major U.S. dialysis providers. In parallel, Rockwell Medical has entered into licensing and distribution agreements across Europe and other regions, enabling access to its therapies through select international partners.
Over its history, Rockwell Medical has evolved its product portfolio via both internal innovation and select divestitures. For example, the company previously marketed Feraheme® for iron deficiency anemia in adults but divested that asset to concentrate on its core nephrology pipeline. Today, Rockwell Medical’s pipeline continues to advance next-generation formulations aimed at improving patient outcomes and reducing treatment burden for those with chronic kidney disease.
Rockwell Medical is led by an experienced management team with deep expertise in renal care and pharmaceutical commercialization. The company’s executive leadership drives both clinical development and commercial strategy, working closely with dialysis providers, physicians and regulatory authorities to expand the availability of its therapies. Through ongoing research and global partnerships, Rockwell Medical remains committed to delivering novel solutions for patients undergoing dialysis.
